Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Economic assessment of pulsed dose-rate (PDR) brachytherapy with optimized dose distribution for cervix carcinoma].
Remonnay R, Morelle M, Pommier P, Haie-Meder C, Quetin P, Kerr C, Delannes M, Castelain B, Peignaux K, Kirova Y, Romestaing P, Williaume D, Krzisch C, Thomas L, Lang P, Baron MH, Cussac A, Lesaunier F, Maillard S, Barillot I, Charra-Brunaud C, Carrère MO, Peiffert D. Remonnay R, et al. Among authors: kerr c. Cancer Radiother. 2010 Jun;14(3):161-8. doi: 10.1016/j.canrad.2009.11.004. Epub 2010 Mar 4. Cancer Radiother. 2010. PMID: 20206571 Clinical Trial. French.
[Radiotherapy of cervix and endometrial carcinoma].
Barillot I, Haie-Méder C, Charra Brunaud C, Peignaux K, Kerr C, Thomas L. Barillot I, et al. Among authors: kerr c. Cancer Radiother. 2016 Sep;20 Suppl:S189-95. doi: 10.1016/j.canrad.2016.07.011. Epub 2016 Aug 11. Cancer Radiother. 2016. PMID: 27523423 French.
PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients.
de la Rochefordiere A, Kamal M, Floquet A, Thomas L, Petrow P, Petit T, Pop M, Fabbro M, Kerr C, Joly F, Sevin E, Maillard S, Curé H, Weber B, Brunaud C, Minsat M, Gonzague L, Berton-Rigaud D, Aumont M, Gladieff L, Peignaux K, Bernard V, Leroy Q, Bieche I, Margogne A, Nadan A, Fourchotte V, Diallo A, Asselain B, Plancher C, Armanet S, Beuzeboc P, Scholl SM. de la Rochefordiere A, et al. Among authors: kerr c. Clin Cancer Res. 2015 Jun 1;21(11):2530-7. doi: 10.1158/1078-0432.CCR-14-2368. Epub 2015 Feb 27. Clin Cancer Res. 2015. PMID: 25724520 Clinical Trial.
Inter-clinician variability in making dosimetric decisions in pediatric treatment: a balance between efficacy and late effects.
Padovani L, Huchet A, Claude L, Bernier V, Quetin P, Mahe M, Laprie A, Kerr C, Bondiau PY, Delarue A, Coze C, Gibon D, Barteau C, Maire JP, Carrie C, Muracciole X. Padovani L, et al. Among authors: kerr c. Radiother Oncol. 2009 Nov;93(2):372-6. doi: 10.1016/j.radonc.2009.05.024. Epub 2009 Aug 3. Radiother Oncol. 2009. PMID: 19647884
Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC).
Mignotte H, Lasset C, Bonadona V, Lesur A, Luporsi E, Rodier JF, Cutuli B, Lasry S, Mauriac L, Granon C, Kerr C, Giard S, Hill C, de Lafontan B, de Gislain C, D'Anjou J, Fondrinier E, Lefeuvre C, Parache RM, Chauvin F. Mignotte H, et al. Among authors: kerr c. Int J Cancer. 1998 May 4;76(3):325-30. doi: 10.1002/(sici)1097-0215(19980504)76:3<325::aid-ijc7>3.0.co;2-x. Int J Cancer. 1998. PMID: 9579567
1,136 results